Systematic Review of Intralesional Therapies for Cutaneous Warts.

Autor:	Mullen SA; College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA., Myers EL; University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA., Brenner RL; College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA., Nguyen KT; College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA., Harper TA; Fischell Department of Bioengineering, University of Maryland, College Park, Maryland, USA., Welsh D; Fischell Department of Bioengineering, University of Maryland, College Park, Maryland, USA., Keffer S; College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska, USA., Mueller J; Fischell Department of Bioengineering, University of Maryland, College Park, Maryland, USA., Whitley MJ; Department of Dermatology, Duke University School of Medicine, Durham, North Carolina, USA.
Jazyk:	angličtina
Zdroj:	JID innovations : skin science from molecules to population health [JID Innov] 2024 Jan 24; Vol. 4 (3), pp. 100264. Date of Electronic Publication: 2024 Jan 24 (Print Publication: 2024).
DOI:	10.1016/j.xjidi.2024.100264
Abstrakt:	Intralesional therapies are used for recalcitrant warts, but no Food and Drug Administration-approved treatment exists nor is there consensus regarding the most efficacious therapy. Therefore, this systematic review aims to summarize efficacy and adverse events reported in 62 randomized controlled trials (RCTs) of intralesional therapies for cutaneous warts. The most studied intralesional therapies included measles, mumps, rubella (MMR) vaccine (n = 24 studies), purified protein derivative (PPD) (n = 19 studies), vitamin D3 (n = 15 studies), and Candida antigen (n = 14 studies). Most studies included adult and pediatric patients or adults alone, with only 4 studies on pediatric patients alone. MMR vaccine was the most studied treatment (n = 853 patients). MMR had a complete response rate of 27-90%. The next most common treatment, PPD, had a complete response rate of 45-87%. Other treatments included Candida antigen and vitamin D3, with complete response rates of 25-84% and 40-96%, respectively. The most frequent side effects were injection-site reactions and flu-like symptoms. This systematic review represents a useful summary of intralesional therapy RCTs for clinician reference. This study also highlights the lack of large multi-institutional RCTs, despite many patients being treated for this widespread problem. (© 2024 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu